Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 22,951 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $10,362,498.20. This represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The shares were sold at an average price of $41.98, for a total value of $710,511.50.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $43.45 on Thursday. The business has a 50 day moving average of $41.20 and a 200-day moving average of $39.49. Vera Therapeutics, Inc. has a 1 year low of $18.76 and a 1 year high of $56.05. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. The company has a market capitalization of $3.10 billion, a P/E ratio of -9.32 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the business earned ($0.72) earnings per share. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VERA. GAMMA Investing LLC boosted its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the fourth quarter worth approximately $46,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics during the second quarter worth approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics during the fourth quarter worth approximately $71,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on VERA. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. HC Wainwright upped their target price on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a report on Wednesday, March 11th. Bank of America upped their target price on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, The Goldman Sachs Group upped their target price on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a report on Friday, December 19th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $81.45.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.